# EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS

RALPH A. DEFRONZO, M.D., ANITA M. GOODMAN, M.D., AND THE MULTICENTER METFORMIN STUDY GROUP*

**Abstract** *Background. Sulfonylurea drugs have been the only oral therapy available for patients with non-insulin-dependent diabetes mellitus (NIDDM) in the United States. Recently, however, metformin has been approved for the treatment of NIDDM.*

*Methods. We performed two large, randomized, parallel-group, double-blind, controlled studies in which metformin or another treatment was given for 29 weeks to moderately obese patients with NIDDM whose diabetes was inadequately controlled by diet (protocol 1: metformin vs. placebo; 289 patients), or diet plus glyburide (protocol 2: metformin and glyburide vs. metformin vs. glyburide; 632 patients). To determine efficacy we measured plasma glucose (while the patients were fasting and after the oral administration of glucose), lactate, lipids, insulin, and glycosylated hemoglobin before, during, and at the end of the study.*

*Results. In protocol 1, at the end of the study the 143 patients in the metformin group, as compared with the 146 patients in the placebo group, had lower mean (±SE) fasting plasma glucose concentrations (189±5 vs. 244±6 mg per deciliter [10.6±0.3 vs. 13.7±0.3 mmol per liter], $P<0.001$) and glycosylated hemoglobin values (7.1±0.1 percent vs. 8.6±0.2 percent, $P<0.001$). In protocol 2, the 213 patients given metformin and glyburide, as compared with the 209 patients treated with glyburide alone, had lower mean fasting plasma glucose concentrations (187±4 vs. 261±4 mg per deciliter [10.5±0.2 vs. 14.6±0.2 mmol per liter], $P<0.001$) and glycosylated hemoglobin values (7.1±0.1 percent vs. 8.7±0.1 percent, $P<0.001$). The effect of metformin alone was similar to that of glyburide alone. Eighteen percent of the patients given metformin and glyburide had symptoms compatible with hypoglycemia, as compared with 3 percent in the glyburide group and 2 percent in the metformin group.*

*In both protocols the patients given metformin had statistically significant decreases in plasma total and low-density lipoprotein cholesterol and triglyceride concentrations, whereas the values in the respective control groups did not change. There were no significant changes in fasting plasma lactate concentrations in any of the groups.*

*Conclusions. Metformin monotherapy and combination therapy with metformin and sulfonylurea are well tolerated and improve glycemic control and lipid concentrations in patients with NIDDM whose diabetes is poorly controlled with diet or sulfonylurea therapy alone. (N Engl J Med 1995;333:541-9.)*

IN the United States patients with non-insulin-dependent diabetes mellitus (NIDDM) are usually treated with diet and a sulfonylurea drug.[1] However, approximately 30 percent of patients initially treated with a sulfonylurea drug have a poor response, and in the remaining 70 percent the subsequent failure rate is approximately 4 to 5 percent per year.[2] In most parts of the world, an alternative or additive approach to oral therapy is available in the form of metformin.[3,4] Clinical experience has proved metformin, either alone or in combination with a sulfonylurea, to be safe and efficacious in reducing plasma glucose concentrations in patients with NIDDM.[3-6] Metformin is believed to work by inhibiting hepatic glucose production[7-10] and increasing the sensitivity of peripheral tissue to insulin[8,9,11-13]; it does not stimulate insulin secretion, which explains the absence of hypoglycemia.[3,4,6,14,15] Metformin also has beneficial effects on plasma lipid concentrations[7,14-16] and promotes weight loss.[4] Because the primary action of sulfonylurea drugs is to enhance insulin secretion, whereas metformin exerts its beneficial effects on glycemic control by enhancing peripheral and hepatic sensitivity to insulin,[7-13] metformin should be equally effective when used as monotherapy and in patients receiving a sulfonylurea drug. This report describes the results of two randomized, placebo-controlled, multicenter trials in which moderately obese patients with NIDDM whose diabetes was poorly controlled with diet alone or with diet plus a sulfonylurea drug were treated with metformin for 29 weeks.

From the Diabetes Division, University of Texas Health Science Center, San Antonio (R.A.D.), and Lipha Pharmaceuticals, New York (A.M.G.). Address reprint requests to Dr. DeFronzo at the Diabetes Division, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78284.

Supported by a grant from Lipha Pharmaceuticals, Inc.

Dr. Goodman is the executive vice president and chief operating officer of Lipha Pharmaceuticals.

*The members of the Multicenter Metformin Study Group are listed in the Appendix.

## METHODS

### Subjects

#### *Protocol 1*

A total of 289 obese patients who were treated with diet alone were assigned to protocol 1. After an eight-week phase during which the patients were counseled about the consumption of a hypocaloric diet,[17] 143 patients were randomly assigned to receive metformin and 146 to receive placebo. The base-line characteristics of the two groups of patients are shown in Table 1.

#### *Protocol 2*

A total of 632 patients with NIDDM were assigned to protocol 2: 210 were assigned to receive metformin, 209 to receive glyburide, and 213 to receive both metformin and glyburide (combination therapy). The base-line characteristics of the three groups are also shown in Table 1.

The diagnosis of NIDDM was based on clinical history and the finding of a fasting plasma glucose concentration above 140 mg per deciliter (7.8 mmol per liter) on two occasions. To be included in the study all patients had to lack acceptable glycemic control (fasting plasma glucose, ≥140 mg per deciliter) after eight weeks of dietary therapy (protocol 1) or at least four weeks of dietary therapy plus 20 mg of glyburide per day (protocol 2). Other inclusion criteria included a weight that was 120 to 170 percent of ideal (on the basis of 1983 Metropolitan Life Insurance tables), an age of 40 to 70 years, normal renal function (serum creatinine, ≤1.4 mg per deciliter [124 μmol

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

per liter] in men and ≤1.3 mg per deciliter [115 μmol per liter] in women; and ≤2+ proteinuria), and normal liver function. Patients were excluded if they had any of the following: symptomatic diabetes (polyuria, polydipsia, and weight loss), symptomatic cardiovascular disease, diastolic blood pressure above 100 mm Hg during antihypertensive-drug treatment, or any concurrent medical illness. They were also excluded if they had received insulin therapy within the previous six months, used medications known to affect glucose metabolism, drank three or more alcoholic drinks per day (≥3 oz of alcohol per day), used illicit drugs, or had previously received metformin therapy. Therapy with estrogen and a progestin and chlorthalidone or a thiazide was permitted in patients already taking these drugs as long as the dosage was not changed during the study. The protocols were approved by the institutional review board of each participating center, and all patients gave written informed consent for the study.

## Study Design

### Protocol 1

*Preenrollment dietary-therapy phase (phase I).* Potential study patients initially provided a complete medical history and underwent a physical examination and screening laboratory tests (Fig. 1, top panel). On two occasions the patients kept a three-day dietary log; the patients were then instructed in a hypocaloric diet, which they were told to follow for eight weeks before undergoing randomization. The diet for each patient was designed to provide 20 percent fewer calories than the patient's calculated daily energy expenditure. Fasting plasma glucose concentrations were determined eight and four weeks before randomization and at base line (week 0). At the time of randomization (week 0), each patient again met with the dietitian to reinforce the dietary instructions.

*Randomization.* At the end of phase I, the patients were randomly assigned to treatment with metformin or placebo. Of the 535 patients who entered the preenrollment dietary-therapy phase, 289 went on to the active-treatment phase: 143 were assigned to metformin and 146 to placebo. Of the other 246 patients, 61 decided not to participate and 185 did not meet the entrance criteria, including 74 who were excluded because they had achieved glycemic control and 30 because they had a change in weight (loss or gain) of more than 3 percent.

*Metformin-titration phase (phase II).* After randomization, treatment was initiated with one 850-mg metformin tablet or one identical-appearing placebo tablet daily with the evening meal. After two weeks, the metformin (or placebo) dose was doubled, with one 850-mg tablet also taken with breakfast. After four weeks, the metformin (or placebo) dose was again increased by 850 mg, so that one additional tablet was taken with lunch. The metformin dose was increased in this fashion as long as the fasting plasma glucose concentration exceeded 140 mg per deciliter and the side effects were tolerable.

*Active metformin-treatment phase (phase III).* After the fifth week, the maximal dose of metformin (or placebo) (2550 mg per day) was continued unless side effects (primarily gastrointestinal) dictated a reduction in the dose. The patients were seen every 4 weeks thereafter for a total of 29 weeks.

At randomization the patients provided a medical history and underwent a physical examination (in which height and body weight were determined), routine blood chemical tests, urinalysis, electrocardiography, and a glucose-tolerance test in which 75 g of glucose was administered orally and plasma glucose, insulin, and C-peptide levels were measured at base line and one, two, and three hours later. In addition, a complete blood count was performed and glycosylated hemoglobin; fasting plasma glucose; fasting plasma lactate; fasting serum total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides; serum vitamin $B_{12}$ and folic acid; and plasma metformin were measured.

At each follow-up visit, we obtained information about compliance, drug side effects, and intercurrent medical events; measured blood pressure; and obtained blood samples while the patients were fasting in order to measure glycosylated hemoglobin and plasma glucose and lactate. At week 29, oral glucose-tolerance tests were performed and plasma lipid and serum vitamin $B_{12}$ and folic acid concentrations were measured; plasma metformin was measured at weeks 9, 21, and 29.

### Protocol 2

*Prerandomization phase (phase I).* During a five-week prerandomization phase, 788 patients with NIDDM began (or continued) to take glyburide; patients taking another sulfonylurea drug were switched to glyburide. The dose of glyburide was 5 mg twice daily for the first week and then 10 mg twice daily for the remaining four weeks of phase I (Fig. 1, bottom panel). The patients also kept a three-day dietary log and then met with a dietitian who instructed the patients in a weight-maintaining diet.[17]

*Randomization.* Of the 788 diabetic patients who were enrolled in phase I, 632 entered the active-treatment phase. At week 0, open-label glyburide was discontinued and the patients were randomly assigned to treatment with glyburide plus metformin placebo (209 patients), metformin plus glyburide placebo (210 patients), or metformin plus glyburide (213 patients). Of the other 156 patients who completed phase I, 114 did not meet the randomization criteria (including 37 because they had achieved glycemic control) and 42 decided not to participate.

*Metformin-titration phase (phase II).* After randomization at week 0, the patients began taking one 500-mg tablet of metformin or one placebo tablet with their evening meal. After one week the metformin (or placebo) dose was increased to 1000 mg per day by adding a 500-mg tablet to the breakfast meal. After two weeks the metformin (or placebo) dose was increased to 1500 mg per day by adding a 500-mg tablet to be taken at lunch. After three weeks the dose was increased to 2000 mg per day by adding a second 500-mg tablet to be taken with the evening meal, and after four weeks the daily dose was increased to 2500 mg by adding a second 500-mg tablet to the breakfast dose. The daily dose was increased in this fashion to a maximum of 2500 mg of metformin (or five placebo tablets) as

*Table 1. Base-Line Characteristics of the Patients with NIDDM.**

| Characteristic | Protocol 1 | | Protocol 2† | | |
|---|---|---|---|---|---|
| | Placebo (N = 146) | Metformin (N = 143) | Glyburide (N = 209) | Metformin (N = 210) | Metformin + Glyburide (N = 213) |
| Age (yr) | 53±1 | 53±1 | 56±1 | 55±1 | 55±1 |
| Sex (M/F) | 62/84 | 62/81 | 103/106 | 96/114 | 98/115 |
| Weight (kg) | 92.2±1.2 | 94.4±1.1 | 92.6±1.0 | 92.6±1.0 | 92.1±1.1 |
| Body-mass index‡ | 29.2±0.3 | 29.9±0.3 | 29.1±0.3 | 29.4±0.3 | 29.0±0.3 |
| Duration of diabetes (yr) | 6.0±0.6 | 6.0±0.5 | 8.7±0.4 | 8.4±0.4 | 7.8±0.4 |
| Family history of diabetes (%) | 70 | 80 | 72 | 72 | 75 |
| Fasting plasma glucose (mg/dl) | 238±6 | 241±5 | 247±3 | 254±4 | 251±4 |
| 2-hr plasma glucose (mg/dl) | 368±8 | 383±8 | 399±6 | 398±6 | 391±6 |
| Glycosylated hemoglobin (%) | 8.2±0.2 | 8.4±0.1 | 8.5±0.1 | 8.9±0.1 | 8.8±0.1 |
| Fasting plasma insulin (μU/ml) | 15±1 | 13±1 | 16±1 | 18±1 | 17±1 |
| Plasma C peptide (ng/ml) | 2.7±0.1 | 2.7±0.1 | 2.8±0.1 | 2.9±0.1 | 2.8±0.1 |
| Plasma total cholesterol (mg/dl) | 212±4 | 211±3 | 215±3 | 212±3 | 216±3 |
| Plasma LDL cholesterol (mg/dl) | 138±3 | 136±3 | 136±3 | 134±3 | 137±3 |
| Plasma HDL cholesterol (mg/dl) | 41±1 | 39±1 | 37±1 | 37±1 | 39±1 |
| Plasma triglycerides (mg/dl) | 185±9 | 209±15 | 210±8 | 231±12 | 216±10 |

*Plus–minus values are means ±SE. LDL denotes low-density lipoprotein, and HDL high-density lipoprotein. To convert values for glucose to millimoles per liter, multiply by 0.056; to convert values for total cholesterol, LDL cholesterol, and HDL cholesterol to millimoles per liter, multiply by 0.0259; to convert values for triglycerides to millimoles per liter, multiply by 0.011; and to convert values for insulin to picomoles per liter, multiply by 6.

†Base-line measurements were made while all patients were taking 20 mg of glyburide per day.

‡Defined as the weight in kilograms divided by the square of the height in meters.

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.




*Figure 1. Design of Protocols 1 and 2.*

long as the fasting plasma glucose concentration exceeded 140 mg per deciliter. Throughout this period and for the remainder of the study, the patients continued to take four tablets of glyburide (20 mg per day) or placebo per day, according to their treatment assignment.

*Active metformin-treatment phase (phase III).* After the fifth week, the patients took the maximal dose of metformin (2500 mg per day) unless side effects dictated a reduction in the dose. The patients were seen every 4 weeks thereafter for a total of 29 weeks. At these visits, the patients were questioned, examined, and studied as described in protocol 1.

### Analytic Methods

Plasma glucose was measured enzymatically with a Hitachi Analyzer (model 736.50, Boehringer–Mannheim Diagnostics, Indianapolis). Glycosylated hemoglobin was measured by ion-exchange high-performance liquid chromatography with a Bio-Rad Diamat Analyzer (Bio-Rad, Hercules, Calif.) (range for normal subjects, 3.3 to 6.8 percent; mean value, 4.7 percent). Plasma free insulin (Coat-A-Count, Diagnostic Products Corporation, Los Angeles) and C peptide (C-peptide RAI Kit, Incstar, Stillwater, Minn.) were measured by radioimmunoassay after plasma was treated with polyethylene glycol. Plasma total cholesterol and triglycerides were measured enzymatically with a Cobas Fera analyzer (Boehringer–Mannheim Diagnostics). Plasma HDL cholesterol was measured enzymatically with a Cobas Fera analyzer after precipitation with dextran sulfate–manganese chloride. Plasma LDL cholesterol was calculated with the Friedwald equation. Serum folic acid and vitamin $B_{12}$ were measured by radioimmunoassay (Bio-Rad Quantaphase $B_{12}$–Folate radioimmunoassay kit). Plasma lactate was measured enzymatically with a Cobas Mira analyzer (Sigma Diagnostics, St. Louis). Serum metformin was measured with modified high-performance liquid chromatography.[18]

### Statistical Analysis

The primary analysis was an intention-to-treat analysis in which the final visit (week 29, or earlier for patients leaving the study) was the primary end point. For efficacy and safety analyses, any patient who took the study medication and completed at least one visit during the active-treatment phase was included. Absolute values, as well as changes from base-line values, for all efficacy measures were compared. Two analyses were performed: one in which only data available at each visit were analyzed and one in which the last available value was carried forward. In the latter analysis, missing values for evaluations during or at the end of treatment were replaced by the most recent previously recorded value. The results of the two analyses were similar. Statistical comparisons were performed with SAS software.[19] Comparisons within groups were made with a two-tailed paired t-test. For continuous variables, comparisons between groups were made with linear models that included contrasts (LS means in SAS) for pairwise comparisons between the treatment groups. These models included effects of treatment and center (analysis of variance),[20] with selected models including an effect of base-line values (analysis of covariance).[20] All values are given as means ±SE.

## Results

### Protocol 1

#### *Metformin Dose*

At the end of the five-week titration phase 78 percent of the patients assigned to metformin were taking the maximal dose (2550 mg per day), and 85 percent eventually took this dose. At week 29 the mean (±SE) fasting plasma metformin concentrations were 742±182 and 872±99 ng per milliliter in the patients taking 1700 and 2550 mg of metformin per day, respectively.

#### *Body Weight and Blood Pressure*

During the active-treatment phase, the patients in the metformin group lost 0.6±0.3 kg of weight and those in the placebo group lost 1.1±0.2 kg ($P=0.21$). The mean base-line blood pressure (supine) in the metformin and placebo groups was normal and did not change during treatment.

#### *Fasting Plasma Glucose and Insulin Concentrations and Glycosylated Hemoglobin Values*

By week 29 the fasting plasma glucose concentration had decreased by 52±5 mg per deciliter (2.9±0.3 mmol per liter) to 189±5 mg per deciliter (10.6±0.3 mmol per liter) in the metformin group and increased by 6±5 mg per deciliter (0.3±0.3 mmol per liter) to 244±6 mg per deciliter (13.7±0.3 mmol per liter) in the placebo group ($P<0.001$). The respective changes in glycosylated hemoglobin were −1.4±0.1 percent and 0.4±0.1 percent ($P<0.001$). At week 29, 22 percent of the patients treated with metformin had fasting plasma glucose concentrations of 140 mg per deciliter or less, as compared with 6 percent in the placebo group ($P=0.001$).

The fasting plasma glucose and glycosylated hemoglobin values during the active-treatment phase are shown in Figures 2 and 3, respectively. In the metformin group, the fasting plasma glucose concentration declined progressively during the metformin-titration phase, reaching a nadir that was about 55 mg per deciliter (3.1 mmol per liter) below base line between weeks 5 and 9, and remained at this level until the end of the study. The magnitude of the decline in fasting plasma glucose was correlated ($r=-0.551$, $P<0.001$)

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

with the base-line fasting plasma glucose concentration (Fig. 4). The declines in fasting plasma glucose and glycosylated hemoglobin values in the metformin group were independent of age (≥65 years or <65 years), race or ethnic group (white vs. black vs. Hispanic), duration of diabetes (≥10 years or <10 years), base-line body-mass index (the weight in kilograms divided by the square of the height in meters, ≥29 or <29), and base-line plasma lipid and insulin concentrations. The fasting plasma insulin and C-peptide concentrations did not change in either group.

### *Oral Glucose-Tolerance Tests*

The plasma glucose and insulin concentrations (weighted mean of the values at 0, 1, 2, and 3 hours) before and after the oral administration of glucose at base line were similar in the metformin and placebo groups. At week 29 the mean plasma glucose concentration after glucose ingestion had not changed in the placebo group (337±10 vs. 337±7 mg per deciliter [18.9±0.6 vs. 18.9±0.4 mmol per liter]) but had decreased in the metformin group (from 347±7 to 275±7 mg per deciliter [19.3±0.4 to 15.3±0.4 mmol per liter],




*Figure 2. Mean (±SE) Changes in Fasting Plasma Glucose Concentrations in Patients with NIDDM Who Were Enrolled in Protocol 1 or 2.*

*The asterisks indicate significant differences (P<0.001) between the groups in Protocol 1, the daggers significant differences (P<0.001) between the metformin and glyburide groups, the diamonds significant differences (P<0.01) between the metformin and glyburide groups, and the double daggers significant differences (P<0.001) between the combination-therapy and glyburide groups. To convert values for glucose to millimoles per liter, multiply by 0.056.*




*Figure 3. Mean (±SE) Changes in Glycosylated Hemoglobin Values in Patients with NIDDM Who Were Enrolled in Protocol 1 or 2.*

*The asterisks indicate significant differences (P<0.001) between the groups in Protocol 1, the daggers significant differences (P<0.01) between the metformin and glyburide groups, and the double daggers significant differences (P<0.001) between the combination-therapy and glyburide groups.*

P<0.001 for the comparison with placebo); all of the decrease was the result of the decrease in the fasting plasma glucose concentration. The mean plasma insulin concentration did not change in the placebo group and rose slightly in the metformin group (to 36.2±2 from 29±2 μU per milliliter [216±12 from 174±12 pmol per liter], P=0.001 for the comparisons with base line and with placebo). The plasma C-peptide concentrations closely paralleled the plasma insulin concentrations in both groups.

### *Plasma Lipids*

Before treatment the fasting serum total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride concentrations were similar in the metformin and placebo groups (Table 2). There were no changes during treatment in the placebo group. By week 29 the serum total cholesterol, LDL cholesterol, and triglyceride concentrations in the metformin group had decreased and were significantly lower than in the placebo group (Table 2).

### *Fasting Plasma Lactate*

The mean fasting plasma lactate concentrations at base line were slightly elevated in both groups (mean

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.




*Figure 4. Relation between the Decrease in Fasting Plasma Glucose Concentrations at the End of Active Treatment and the Base-Line Concentrations in Patients with NIDDM.*

*The numbers of patients in each subgroup are indicated. Values are means ±SE. To convert values for glucose to millimoles per liter, multiply by 0.056.*

in both groups, 1.41±0.10 mmol per liter; normal, <1.30 mmol per liter). The values were similar at all times during the active-treatment period in both groups.

### *Serum Vitamin $B_{12}$ and Folate*

Serum folate concentrations did not change in either the metformin or placebo groups. The serum vitamin $B_{12}$ concentration at week 29 was lower in the metformin group (by 22 percent) but did not change in the placebo group. There were no changes in hematocrit or hemoglobin in either group.

### *Withdrawal of Patients and Adverse Effects*

Thirty-one patients in the metformin group (22 percent) and 41 patients in the placebo group (28 percent) withdrew from the study before week 29 (Table 3). More patients in the placebo group than in the metformin group withdrew because of treatment failure (18 vs. 2 [12 percent vs. 1 percent], P<0.001). Adverse effects were limited to the digestive system. Diarrhea and nausea were more common in the group receiving metformin, but were characterized as severe in only 8 percent and 4 percent of patients, respectively. The frequency and severity of reported symptoms of hypoglycemia were similar in the metformin and placebo groups (<2 percent). No patient had biochemically documented hypoglycemia.

## Protocol 2

### *Metformin and Glyburide Dose*

At week 29, 90 percent of the patients in the metformin group and 70 percent in the group given metformin plus glyburide were receiving 2500 mg of metformin per day. The mean fasting plasma metformin concentrations in these two groups were 809±60 and 920±75 ng per milliliter, respectively, at this time.

### *Body Weight and Blood Pressure*

There was no significant change in body weight at week 29 in the glyburide group (−0.3±0.2 kg). The

*Table 2. Plasma Lipid and Lactate Concentrations in the Five Groups before and after Treatment for 29 Weeks.**

| Variable | Plasma Total Cholesterol | P Value | Plasma LDL Cholesterol | P Value | Plasma HDL Cholesterol | Plasma Triglycerides | P Value | Plasma Lactate |
|---|---|---|---|---|---|---|---|---|
| | *mg/dl* | | *mg/dl* | | *mg/dl* | *mg/dl* | | *mmol/liter* |
| **Protocol 1** | | | | | | | | |
| Before treatment | | | | | | | | |
| Metformin | 211±3 | | 136±3 | | 39±1 | 209±15 | | 1.41±0.04 |
| Placebo | 212±4 | | 138±3 | | 41±1 | 185±9 | | 1.40±0.04 |
| After treatment | | | | | | | | |
| Metformin | 201±4 | | 123±3 | | 40±1 | 193±10 | | 1.46±0.05 |
| Placebo | 213±4 | 0.005† | 135±3 | 0.01† | 41±1 | 191±10 | | 1.41±0.04 |
| Change | | | | | | | | |
| Metformin | −11±3 | | −11±3 | | 1±1 | −17±12 | | 0.04±0.05 |
| Placebo | 1±3 | 0.001† | −2±2 | 0.019† | −1±1 | 6±7 | | 0.00±0.05 |
| **Protocol 2** | | | | | | | | |
| Before treatment | | | | | | | | |
| Metformin | 212±3 | | 134±3 | | 37±1 | 231±12 | | 1.47±0.04 |
| Glyburide | 215±3 | | 136±3 | | 37±1 | 210±8 | | 1.45±0.03 |
| Metformin + glyburide | 216±3 | | 137±3 | | 39±1 | 216±10 | | 1.45±0.03 |
| After treatment | | | | | | | | |
| Metformin | 208±3 | 0.003‡ | 129±3 | 0.001‡ | 39±1 | 221±13 | 0.004‡ | 1.54±0.04 |
| Glyburide | 220±4 | | 141±3 | | 38±1 | 227±11 | | 1.42±0.04 |
| Metformin + glyburide | 206±3 | 0.001‡ | 128±3 | 0.001‡ | 40±1 | 194±9 | 0.001‡ | 1.51±0.04 |
| Change | | | | | | | | |
| Metformin | −4±2 | 0.011‡ | −6±2 | 0.009‡ | 2±1 | −16±7 | 0.001‡ | 0.08±0.04 |
| Glyburide | 5±2 | | 3±2 | | <1±1 | 21±9 | | −0.01±0.03 |
| Metformin + glyburide | −10±2 | 0.001‡ | −8±2 | 0.001‡ | 1±1 | −20±7 | 0.001‡ | 0.06±0.04 |

*To convert values for total, LDL, and HDL cholesterol to millimoles per liter, multiply by 0.0259, and to convert values for triglycerides to millimoles per liter, multiply by 0.011.

†For the comparison with metformin.

‡For the comparison with glyburide.

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

**LAW FIRMS**
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

**FINANCIAL INSTITUTIONS**
Litigation and bankruptcy checks for companies and debtors.

**E-DISCOVERY AND LEGAL VENDORS**
Sync your system to PACER to automate legal marketing.